Abstract
Importance Coronary heart disease (CHD) is a leading cause of premature mortality globally. Most polygenic risk scores (PRSs) for CHD have been derived in populations of European ancestry. Their utility for CHD risk prediction in other populations is uncertain.
Objective To evaluate the performance of eight established CHD PRSs in an admixed cohort of Mexican adults.
Design, Setting, Participants 133,207 genotyped participants aged 35–79 years from the Mexico City Prospective Study (MCPS), a cohort recruited between 1998–2004, with follow-up for mortality until September 30, 2022.
Exposures Eight PRSs for CHD, comprising between 44 and 6,472,620 single nucleotide polymorphism (SNP) variants, were selected and recreated for MCPS participants.
Main outcomes and measure Premature CHD comprised prior doctor-diagnosed CHD at recruitment or CHD-related death before age 80. Logistic regression adjusted for age, sex, and the first seven genetic principal components (PCs) assessed PRS associations with CHD. Additional analyses evaluated performance by key participant characteristics, and after adjustment for vascular risk factors. Risk discrimination was assessed using C-statistics.
Results Of the participants, 67% were women, the mean (±SD) age was 51±12 years, and Indigenous American ancestry averaged 67%. Premature CHD occurred in 5,163 participants (3.9%), including 1,901 prevalent and 3,479 fatal cases. All eight PRSs were positively and log-linearly associated with CHD, with odds ratios (ORs) per 1 SD increase ranging from 1.05 (95% CI, 1.03–1.08) to 1.29 (95% CI, 1.25–1.33). Associations were consistent across strata of age, ancestry, and relatedness. For six PRSs, however, associations were stronger in men than women (e.g., for the PRS with the strongest overall association: OR 1.37 [1.32–1.43] in men vs. 1.23 [1.18–1.28] in women). Adjustment for vascular risk factors did not substantially alter associations. Models including age, sex, genetic PCs and a PRS achieved an AUC of 0.72.
Conclusion and Relevance In this Mexican population, existing PRSs derived from predominantly European ancestry populations predicted premature CHD independently of established vascular risk factors, particularly in men. Polygenic risk scores better capturing genetic variation in Latin American men and women may further enhance CHD risk prediction among Mexican and other Hispanic populations.
Question To what extent do previously-published coronary heart disease (CHD) polygenic risk scores (PRS) predict CHD risk in an admixed Mexican population?
Findings Among 133,207 Mexican adults aged 36-79 years, eight external PRSs were positively and log-linearly associated with CHD. Six of the eight showed significantly stronger associations with CHD in men compared to women. Multi-ancestry PRSs outperformed Eurocentric-ancestry PRSs.
Meaning PRSs that better capture genetic variation in Latin-American men and women may further enhance CHD risk prediction among Mexican and other Hispanic populations.
Competing Interest Statement
Jonathan Emberson and Rory Collins report grants to the University of Oxford from AstraZeneca and Regeneron Pharmaceuticals. Rory Collins reports having a patent for a statin-related myopathy genetic test licensed to the University of Oxford from Boston Heart Diagnostics (Rory Collins has waived any personal reward with any share in royalty and other payments waived in favour of the Nuffield Department of Population Health, University of Oxford) and being deputy chair of not-for-profit clinical trial company PROTAS, Chief Executive of UK Biobank, and Chair of the steering committee of the ORION-4 clinical trial of inclisiran. All other authors declare no competing interests.
Funding Statement
The study was funded by Mexican Health Ministry; the National Council of Science and Technology for Mexico; Wellcome [058299/Z/99]; Cancer Research UK; the British Heart Foundation [RE/13/1/30181]; and the UK Medical Research Council [MC_UU_00017/2, MR/Z504543/1]. Genotyping was funded through an academic partnership between the National Autonomous University of Mexico, the University of Oxford, Regeneron and AstraZeneca. The computational aspects of this research were supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z and the NIHR Oxford BRC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the Mexican National Council of Science and Technology [0595 P-M], the Mexican Ministry of Health[143300410D0020/153300912X3548/2015; FMED/CI/RGG/083/2017], the Ethics and Research commission from the Medicine Faculty at the National Autonomous University of Mexico (Universidad Nacional Autonoma de Mexico, UNAM) and the University of Oxford [135/2014].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos